In this article, Freis provided a review and assessment of a new antihypertensive drug, guanethidine. Unlike the older ganglion blocking agents, this new drug effectively inhibited the sympathetic system without blocking parasympathetic activity, and therefore had fewer side effects. It soon became the preferred drug for the treatment of the most severe cases of hypertension.
The National Library of Medicine believes this item to be in the public domain. (More information)